Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen, Inc. Again Named One of The Boston Globe's Top Places to Work
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that it has been named one of The Boston Globe's Top Places to Work.
View HTML
Toggle Summary ImmunoGen, Inc. Reports First Quarter Fiscal Year 2015 Financial Results
− Conference Call Today at 8:00 am ET− Advancing pipeline of wholly owned therapeutic candidates: IMGN853 in initial evaluation of efficacy in treatment of targeted ovarian and endometrial cancers; new IMGN529 clinical data to be reported at ASH; dose-finding evaluation of IMGN289 ongoing; IMGN779
View HTML